Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• PratJNew insights into ovarian cancer pathologyAnn Oncol201223Suppl 10x111x11722987944
   PubMedGoogle Scholar
• HollisRLGourleyCGenetic and molecular changes in ovarian cancerCancer Biol Med201613223624727458531
   PubMed Web of Science ®Google Scholar
• LedermannJARajaFAFotopoulouCGonzalez-MartinAColomboNSessaCNewly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi24vi3224078660
   PubMed Web of Science ®Google Scholar
• SymeonidesSGourleyCOvarian cancer molecular stratification and tumor heterogeneity: a necessity and a challengeFront Oncol2015522926557500
   PubMedGoogle Scholar
• WalshTCasadeiSLeeMKMutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProc Natl Acad Sci U S A201110844180321803722006311
   PubMed Web of Science ®Google Scholar
• PratJRibeAGallardoAHereditary ovarian cancerHum Pathol200536886187016112002
   PubMedGoogle Scholar
• TanDSRothermundtCThomasK“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutationsJ Clin Oncol200826345530553618955455
   PubMed Web of Science ®Google Scholar
• LiuGYangDSunYDiffering clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancerPharmacogenomics201213131523153523057551
   PubMedGoogle Scholar
• MikiYSwensenJShattuck-EidensDA strong candidate for the breast and ovarian cancer susceptibility gene BRCA1Science1994266518266717545954
   PubMed Web of Science ®Google Scholar
• ClarkSLRodriguezAMSnyderRRHankinsGDBoehningDStructure-function of the tumor suppressor BRCA1Comput Struct Biotechnol J201211e20120400522737296
   PubMedGoogle Scholar
• HashizumeRFukudaMMaedaIThe RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutationJ Biol Chem200127618145371454011278247
   PubMed Web of Science ®Google Scholar
• MankeIALoweryDMNguyenAYaffeMBBRCT repeats as phosphopeptide-binding modules involved in protein targetingScience2003302564563663914576432
   PubMedGoogle Scholar
• YuXChiniCCHeMMerGChenJThe BRCT domain is a phosphoprotein binding domainScience2003302564563964214576433
   PubMed Web of Science ®Google Scholar
• MezaJEBrzovicPSKingMCKlevitREMapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1J Biol Chem199927495659566510026184
   PubMedGoogle Scholar
• WilliamsRSGreenRGloverJNCrystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1Nat Struct Biol200181083884211573086
   PubMedGoogle Scholar
• ThakurSZhangHBPengYLocalization of BRCA1 and a splice variant identifies the nuclear localization signalMol Cell Biol19971714444528972225
   PubMedGoogle Scholar
• DengCXBrodieSGRoles of BRCA1 and its interacting proteinsBioessays200022872873710918303
   PubMedGoogle Scholar
• CortezDWangYQinJElledgeSJRequirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaksScience199928654421162116610550055
   PubMed Web of Science ®Google Scholar
• AbbottDWThompsonMERobinson-BenionCTomlinsonGJensenRAHoltJTBRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repairJ Biol Chem199927426188081881210373498
   PubMed Web of Science ®Google Scholar
• MoynahanMECuiTYJasinMHomology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutationCancer Res200161124842485011406561
   PubMedGoogle Scholar
• MoynahanMEChiuJWKollerBHJasinMBrca1 controls homology-directed DNA repairMol Cell19994451151810549283
   PubMed Web of Science ®Google Scholar
• FabbroMSavageKHobsonKBRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damageJ Biol Chem200427930312513125815159397
   PubMed Web of Science ®Google Scholar
• XuBKimSKastanMBInvolvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiationMol Cell Biol200121103445345011313470
   PubMed Web of Science ®Google Scholar
• WangBMatsuokaSBallifBAAbraxas and RAP80 form a BRCA1 protein complex required for the DNA damage responseScience200731658281194119817525340
   PubMed Web of Science ®Google Scholar
• RoyRChunJPowellSNBRCA1 and BRCA2: different roles in a common pathway of genome protectionNat Rev Cancer20121216878
   Web of Science ®Google Scholar
• ShahidTSorokaJKongEHStructure and mechanism of action of the BRCA2 breast cancer tumor suppressorNat Struct Mol Biol2014211196296825282148
   PubMedGoogle Scholar
• MoynahanMEPierceAJJasinMBRCA2 is required for homology- directed repair of chromosomal breaksMol Cell20017226327211239455
   PubMed Web of Science ®Google Scholar
• WongAKPeroROrmondePATavtigianSVBartelPLRAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2J Biol Chem19972725131941319449405383
   PubMedGoogle Scholar
• ChenPLChenCFChenYXiaoJSharpZDLeeWHThe BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatmentProc Natl Acad Sci U S A1998959528752929560268
   PubMedGoogle Scholar
• BorkPBlombergNNilgesMInternal repeats in the BRCA2 protein sequenceNat Genet199613122238673099
   PubMedGoogle Scholar
• BignellGMicklemGStrattonMRAshworthAWoosterRThe BRC repeats are conserved in mammalian BRCA2 proteinsHum Mol Genet19976153589002670
   PubMedGoogle Scholar
• DaviesAAMassonJYMcIlwraithMJRole of BRCA2 in control of the RAD51 recombination and DNA repair proteinMol Cell20017227328211239456
   PubMed Web of Science ®Google Scholar
• EsashiFGalkinVEYuXEgelmanEHWestSCStabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2Nat Struct Mol Biol200714646847417515904
   PubMed Web of Science ®Google Scholar
• YangHJeffreyPDMillerJBRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structureScience200229755881837184812228710
   PubMed Web of Science ®Google Scholar
• YoshidaKMikiYRole of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damageCancer Sci2004951186687115546503
   PubMed Web of Science ®Google Scholar
• YuanSSLeeSYChenGSongMTomlinsonGELeeEYBRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivoCancer Res199959153547355110446958
   PubMed Web of Science ®Google Scholar
• AbbottDWFreemanMLHoltJTDouble-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cellsJ Natl Cancer Inst199890139789859665145
   PubMedGoogle Scholar
• ForayNRandrianarisonVMarotDPerricaudetMLenoirGFeunteunJGamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2Oncogene199918517334734210602489
   PubMedGoogle Scholar
• KingMCMarksJHMandellJBNew York Breast Cancer Study GroupBreast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2Science2003302564564364614576434
   PubMed Web of Science ®Google Scholar
• ChenSParmigianiGMeta-analysis of BRCA1 and BRCA2 penetranceJ Clin Oncol200725111329133317416853
   PubMed Web of Science ®Google Scholar
• PenningtonKPSwisherEMHereditary ovarian cancer: beyond the usual suspectsGynecol Oncol2012124234735322264603
   PubMed Web of Science ®Google Scholar
• GaytherSAWarrenWMazoyerSGermline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlationNat Genet19951144284337493024
   PubMed Web of Science ®Google Scholar
• ThompsonDEastonDBreast Cancer Linkage ConsortiumVariation in BRCA1 cancer risks by mutation positionCancer Epidemiol Biomarkers Prev200211432933611927492
   PubMedGoogle Scholar
• GaytherSAMangionJRussellPVariation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 geneNat Genet19971511031058988179
   PubMedGoogle Scholar
• RebbeckTRMitraNWanFAssociation of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancerJAMA2015313131347136125849179
   PubMed Web of Science ®Google Scholar
• BoydJSonodaYFedericiMGClinicopathologic features of BRCA-linked and sporadic ovarian cancerJAMA2000283172260226510807385
   PubMedGoogle Scholar
• GarberJEOffitKHereditary cancer predisposition syndromesJ Clin Oncol200523227629215637391
   PubMed Web of Science ®Google Scholar
• AlsopKFeredaySMeldrumCBRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupJ Clin Oncol201230212654266322711857
   PubMed Web of Science ®Google Scholar
• RamusSJGaytherSAThe contribution of BRCA1 and BRCA2 to ovarian cancerMol Oncol20093213815019383375
   PubMed Web of Science ®Google Scholar
• The Breast Cancer Linkage ConsortiumCancer risks in BRCA2 mutation carriersJ Natl Cancer Inst199991151310131610433620
   PubMedGoogle Scholar
• TakahashiHChiuHCBanderaCAMutations of the BRCA2 gene in ovarian carcinomasCancer Res19965612273827418665505
   PubMedGoogle Scholar
• YangDKhanSSunYAssociation of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancerJAMA2011306141557156521990299
   PubMed Web of Science ®Google Scholar
• RischHAMcLaughlinJRColeDEPrevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancerAm J Hum Genet200168370071011179017
   PubMed Web of Science ®Google Scholar
• PratJOvarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresVirchows Arch2012460323724922322322
   PubMed Web of Science ®Google Scholar
• GilksCBPratJOvarian carcinoma pathology and genetics: recent advancesHum Pathol20094091213122319552940
   PubMed Web of Science ®Google Scholar
• KindelbergerDWLeeYMironAIntraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationshipAm J Surg Pathol200731216116917255760
   PubMed Web of Science ®Google Scholar
• LeeYMironADrapkinRA candidate precursor to serous carcinoma that originates in the distal fallopian tubeJ Pathol20072111263517117391
   PubMed Web of Science ®Google Scholar
• KurmanRJShih IeMThe origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theoryAm J Surg Pathol201034343344320154587
   PubMed Web of Science ®Google Scholar
• PiekJMvan DiestPJZweemerRPDysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerJ Pathol2001195445145611745677
   PubMed Web of Science ®Google Scholar
• SomiglianaEViganoPParazziniFStoppelliSGiambattistaEVercelliniPAssociation between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidenceGynecol Oncol2006101233134116473398
   PubMed Web of Science ®Google Scholar
• MarquezRTBaggerlyKAPattersonAPPatterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colonClin Cancer Res200511176116612616144910
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• TothillRWTinkerAVGeorgeJNovel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcomeClin Cancer Res200814165198520818698038
   PubMed Web of Science ®Google Scholar
• ZornKKBonomeTGangiLGene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancerClin Cancer Res200511186422643016166416
   PubMed Web of Science ®Google Scholar
• BoltonKLChenevix-TrenchGGohCAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerJAMA2012307438239022274685
   PubMed Web of Science ®Google Scholar
• KanchiKLJohnsonKJLuCIntegrated analysis of germline and somatic variants in ovarian cancerNat Commun20145315624448499
   PubMed Web of Science ®Google Scholar
• CormioGRossiCCazzollaADistant metastases in ovarian carcinomaInt J Gynecol Cancer200313212512912657111
   PubMed Web of Science ®Google Scholar
• GourleyCMichieCORoxburghPIncreased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeJ Clin Oncol201028152505251120406939
   PubMed Web of Science ®Google Scholar
• SekineMYoshiharaKKomataDHainoKNishinoKTanakaKIncreased incidence of brain metastases in BRCA1-related ovarian cancersJ Obstet Gynaecol Res201339129229622889437
   PubMedGoogle Scholar
• VenckenPMKriegeMHoogwerfDChemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsAnn Oncol20112261346135221228333
   PubMed Web of Science ®Google Scholar
• WangYBernhardyAJCruzCThe BRCA1-Delta11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatinCancer Res20167692778279027197267
   PubMed Web of Science ®Google Scholar
• DimitrovaDRuscitoIOlekSGermline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) ConsortiumTumour Biol2016379123291233727297669
   PubMedGoogle Scholar
• DrostRBouwmanPRottenbergSBRCA1 RING function is essential for tumor suppression but dispensable for therapy resistanceCancer Cell201120679780922172724
   PubMedGoogle Scholar
• DrostRDhillonKKvan der GuldenHBRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1J Clin Invest201612682903291827454287
   PubMed Web of Science ®Google Scholar
• StruewingJPAbeliovichDPeretzTThe carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individualsNat Genet19951121982007550349
   PubMedGoogle Scholar
• RoaBBBoydAAVolcikKRichardsCSAshkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nat Genet19961421851878841191
   PubMed Web of Science ®Google Scholar
• TinkerAVGebskiVFitzharrisBPhase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel – ANZGOG 02-01Gynecol Oncol2007104364765317079006
   PubMedGoogle Scholar
• KatsumataNTsunematsuRTanakaKA phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative studyAnn Oncol200011121531153611205459
   PubMed Web of Science ®Google Scholar
• Gynecologic Oncology Group; MarkmanMBlessingJPhase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group studyGynecol Oncol2006101343644016325893
   PubMedGoogle Scholar
• WeaverBAHow taxol/paclitaxel kills cancer cellsMol Biol Cell201425182677268125213191
   PubMed Web of Science ®Google Scholar
• QuinnJEKennedyRDMullanPBBRCA1 functions as a differential modulator of chemotherapy-induced apoptosisCancer Res200363196221622814559807
   PubMed Web of Science ®Google Scholar
• StordalBDaveyRA systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1Curr Cancer Drug Targets20099335436519442054
   PubMedGoogle Scholar
• SaikiYOgawaTShigaKSunamuraMKobayashiTHoriiAA human head and neck squamous cell carcinoma cell line with acquired cis-diamminedichloroplatinum-resistance shows remarkable upregulation of BRCA1 and hypersensitivity to taxaneInt J Otolaryngol2011201152185222046189
   PubMedGoogle Scholar
• GilmorePMMcCabeNQuinnJEBRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3Cancer Res200464124148415415205325
   PubMedGoogle Scholar
• TassonePTagliaferriPPerricelliABRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBr J Cancer20038881285129112698198
   PubMed Web of Science ®Google Scholar
• ChabalierCLamareCRaccaCPrivatMValetteALarminatFBRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistanceCell Cycle2006591001100716639080
   PubMed Web of Science ®Google Scholar
• SungMGiannakakouPBRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signalingOncogene201433111418142823524581
   PubMedGoogle Scholar
• FedierASteinerRASchwarzVALenherrLHallerUFinkDThe effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cellsInt J Oncol20032251169117312684687
   PubMedGoogle Scholar
• ZhouCSmithJLLiuJRole of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1Oncogene200322162396240412717416
   PubMedGoogle Scholar
• KurebayashiJYamamotoYKurosumiMLoss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanesAnticancer Res2006261b69570116739340
   PubMedGoogle Scholar
• QuinnJEJamesCRStewartGEBRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapyClin Cancer Res200713247413742018094425
   PubMedGoogle Scholar
• TanDSYapTAHutkaMImplications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancerEur J Cancer20134961246125323265709
   PubMedGoogle Scholar
• PisanoCCecereSCDi NapoliMClinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancerJ Drug Deliv2013201389814623577259
   PubMedGoogle Scholar
• ShawHMHallMEmerging treatment options for recurrent ovarian cancer: the potential role of olaparibOnco Targets Ther201361197120624043945
   PubMed Web of Science ®Google Scholar
• AdamsSFMarshEBElmasriWA high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerGynecol Oncol2011123348649121945552
   PubMed Web of Science ®Google Scholar
• SafraTBorgatoLNicolettoMOBRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicinMol Cancer Ther201110102000200721835933
   PubMed Web of Science ®Google Scholar
• FujiwaraKArmstrongDMorganMMarkmanMPrinciples and practice of intraperitoneal chemotherapy for ovarian cancerInt J Gynecol Cancer200717112017291226
   PubMed Web of Science ®Google Scholar
• HowellSBPharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancerInt J Gynecol Cancer200818suppl 1202518336394
   PubMedGoogle Scholar
• YanTDCaoCQMunkholm-LarsenSA pharmacological review on intraperitoneal chemotherapy for peritoneal malignancyWorld J Gastrointest Oncol20102210911621160929
   PubMedGoogle Scholar
• DedrickRLMyersCEBungayPMDeVitaVTJrPharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancerCancer Treat Rep1978621111626987
   PubMedGoogle Scholar
• AlbertsDSLiuPYHanniganEVIntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancerN Engl J Med199633526195019558960474
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• MarkmanMBundyBNAlbertsDSPhase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJ Clin Oncol20011941001100711181662
   PubMed Web of Science ®Google Scholar
• PolyzosATsavarisNKosmasCA comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancerOncology199956429129610343192
   PubMedGoogle Scholar
• YenMSJuangCMLaiCRChaoGCNgHTYuanCCIntraperi-toneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancerInt J Gynaecol Obstet2001721556011146078
   PubMedGoogle Scholar
• WrightAACroninAMilneDEUse and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancerJ Clin Oncol201533262841284726240233
   PubMed Web of Science ®Google Scholar
• GourleyCWalkerJLMackayHJUpdate on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancerAm Soc Clin Oncol Educ Book20163514315127249695
   PubMedGoogle Scholar
• LesnockJLDarcyKMTianCBRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group StudyBr J Cancer201310861231123723462720
   PubMed Web of Science ®Google Scholar
• KehoeSHookJNankivellMPrimary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialLancet2015386999024925726002111
   PubMed Web of Science ®Google Scholar
• SatoSItamochiHNeoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapyTher Adv Med Oncol20146629330425364394
   PubMed Web of Science ®Google Scholar
• VergoteITropeCGAmantFNeoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med20103631094395320818904
   PubMed Web of Science ®Google Scholar
• MeyerLACroninAMSunCCUse and effectiveness of neo-adjuvant chemotherapy for treatment of ovarian cancerJ Clin Oncol Epub201696
   Google Scholar
• GorodnovaTVSokolenkoAPIvantsovAOHigh response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutationCancer Lett2015369236336726342406
   PubMed Web of Science ®Google Scholar
• SchwarzRFNgCKCookeSLSpatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysisPLoS Med2015122e100178925710373
   PubMed Web of Science ®Google Scholar
• BlagdenSPHarnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancerFront Oncol2015514926175968
   PubMed Web of Science ®Google Scholar
• KyleSThomasHDMitchellJCurtinNJExploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancerBr J Radiol200881Spec1S6S1118820000
   PubMedGoogle Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP- ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• StromCEJohanssonFUhlenMSzigyartoCAErixonKHelledayTPoly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediateNucleic Acids Res20113983166317521183466
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• SwisherEMLinKKOzaAMRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol2017181758727908594
   PubMed Web of Science ®Google Scholar
• MirzaMRMonkBJHerrstedtJNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerN Engl J Med2016375222154216427717299
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
   PubMed Web of Science ®Google Scholar
• ColemanRLSillMWBell-McGuinnKA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group studyGynecol Oncol2015137338639125818403
   PubMed Web of Science ®Google Scholar
• LedermannJAHarterPGourleyCOverall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialLancet Oncol2016
   Google Scholar
• DhillonKKSwisherEMTaniguchiTSecondary mutations of BRCA1/2 and drug resistanceCancer Sci2011102466366921205087
   PubMed Web of Science ®Google Scholar
• SwisherEMSakaiWKarlanBYWurzKUrbanNTaniguchiTSecondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceCancer Res20086882581258618413725
   PubMed Web of Science ®Google Scholar
• SakaiWSwisherEMKarlanBYSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature200845171821116112018264087
   PubMed Web of Science ®Google Scholar
• SakaiWSwisherEMJacquemontCFunctional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinomaCancer Res200969166381638619654294
   PubMed Web of Science ®Google Scholar
• EdwardsSLBroughRLordCJResistance to therapy caused by intragenic deletion in BRCA2Nature200845171821111111518264088
   PubMed Web of Science ®Google Scholar
• BarberLJSandhuSChenLSecondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorJ Pathol2013229342242923165508
   PubMed Web of Science ®Google Scholar
• NorquistBWurzKAPennilCCSecondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasJ Clin Oncol201129223008301521709188
   PubMed Web of Science ®Google Scholar
• PatchAMChristieELEtemadmoghadamDWhole-genome characterization of chemoresistant ovarian cancerNature2015521755348949426017449
   PubMed Web of Science ®Google Scholar
• LangdonSPLawrieSSHayFGCharacterization and properties of nine human ovarian adenocarcinoma cell linesCancer Res19884821616661723167863
   PubMed Web of Science ®Google Scholar
• StordalBTimmsKFarrellyABRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutationMol Oncol20137356757923415752
   PubMedGoogle Scholar
• Ben DavidYChetritAHirsh-YechezkelGEffect of BRCA mutations on the length of survival in epithelial ovarian tumorsJ Clin Oncol200220246346611786575
   PubMed Web of Science ®Google Scholar
• RubinSCBenjaminIBehbakhtKClinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1N Engl J Med199633519141314168875917
   PubMedGoogle Scholar
• Candido-dos-ReisFJSongHGoodeELGermline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerClin Cancer Res201521365265725398451
   PubMedGoogle Scholar
• BigliaNSgandurraPBounousVEOvarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survivalEcancermedicalscience20161063927350785
   PubMed Web of Science ®Google Scholar
• HarterPJohnsonTBerton-RigaudDBRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyGynecol Oncol2016140344344926740259
   PubMed Web of Science ®Google Scholar
• ZhongQPengHLZhaoXZhangLHwangWTEffects of BRCA1-and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysisClin Cancer Res201521121122025348513
   PubMedGoogle Scholar
• VenckenPMReitsmaWKriegeMOutcome of BRCA1-compared with BRCA2-associated ovarian cancer: a nationwide study in the NetherlandsAnn Oncol20132482036204223543211
   PubMedGoogle Scholar
• SynowiecAWcisloGBodnarLClinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patientsHered Cancer Clin Pract201614126753012
   PubMedGoogle Scholar
• XuKYangSZhaoYPrognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysisOncotarget20178128530227690218
   PubMedGoogle Scholar
• StricklandKCHowittBEShuklaSAAssociation and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancerOncotarget2016712135871359826871470
   PubMedGoogle Scholar
• McLaughlinJRRosenBMoodyJLong-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2J Natl Cancer Inst2013105214114823257159
   PubMedGoogle Scholar
• ChetritAHirsh-YechezkelGBen-DavidYLubinFFriedmanESadetzkiSEffect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancerJ Clin Oncol2008261202518165636
   PubMedGoogle Scholar
• SunCLiNDingDThe role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysisPLoS One201495e9528524788697
   PubMed Web of Science ®Google Scholar
• LacourRAWestinSNMeyerLAImproved survival in non- Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutationsGynecol Oncol2011121235836321276604
   PubMedGoogle Scholar
• HymanDMZhouQIasonosAImproved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerCancer2012118153703370922139894
   PubMedGoogle Scholar
• PalTPermuth-WeyJKapoorRCantorASutphenRImproved survival in BRCA2 carriers with ovarian cancerFam Cancer20076111311917160431
   PubMedGoogle Scholar